Avidity Biosciences, Inc. 8-K

What Happened
Avidity Biosciences, Inc. announced that at a virtual special meeting of stockholders on February 26, 2026, shareholders approved the Agreement and Plan of Merger with Novartis AG and the Separation and Distribution Agreement governing its planned spin-off (SpinCo, renamed Atrium Therapeutics, Inc.). The Merger Agreement and Separation Agreement were originally dated October 25, 2025. The approval satisfies the stockholder vote condition required to proceed with the transactions.

Key Details

• Special meeting date: February 26, 2026 (virtual); record date: January 29, 2026.
• Shares eligible to vote: 154,740,172; shares present or by proxy: 123,715,570 (≈79.95% of eligible shares).
• Proposal 1 (adopt Merger and Separation Agreements): For 123,351,048; Against 8,090; Abstentions 60,331; Broker non‑votes 296,100 — Proposal approved.
• Advisory Proposal on merger‑related executive compensation: For 101,383,553; Against 21,654,186; Abstentions 381,730; Broker non‑votes 296,100 — advisory approval.
• SpinCo background: originally formed as Bryce Therapeutics, Inc.; name changed to Atrium Therapeutics, Inc. on December 8, 2025.

Why It Matters
This vote clears a key corporate governance hurdle for Avidity’s planned merger with Novartis and the related separation/spin‑off. For investors, the approved agreements mean the company can move forward toward completing the transactions as structured in the October 25, 2025 agreements; the filing does not disclose deal consideration, closing timing, or financial terms in this 8‑K. The non‑binding advisory vote on compensation passed, which signals shareholder acceptance of executive payouts tied to the transactions but does not change contractual obligations.